@article{68109beb229e4319916c961b98cb25e4,
title = "Classification of the epilepsies: New concepts for discussion and debate—Special report of the ILAE Classification Task Force of the Commission for Classification and Terminology",
abstract = "The ILAE Task Force on Classification presents a road map for the development of an updated, relevant classification of the epilepsies. Our objective is to explain the process to date and the plan moving forward as well as to invite further discussion about the newly proposed terms and concepts. Here, we present our response to feedback about the 2010 Organization of the Epilepsies and clarify the reintroduction of the word “classification” to map out a framework for epilepsy diagnosis. We introduce some new concepts and suggest four diagnostic levels: seizure type, epilepsy category, epilepsy syndrome, and epilepsy with (specific) etiology to denote specific levels of diagnosis. We expand the etiological categories to six, focusing on those with treatment implications. Finally, we discuss the changes in terminology originally suggested and modifications in response to comments from the epilepsy community. We welcome feedback and discussion from the global epilepsy community, particularly for the new suggested terms, so that we can cement a classification that both reflects current thinking and scientific understanding and provides a dynamic, evolving framework.",
keywords = "Classification, Epilepsy syndromes, Etiology, Terminology",
author = "Scheffer, {Ingrid E.} and Jacqueline French and Edouard Hirsch and Satish Jain and Mathern, {Gary W.} and Mosh{\'e}, {Solomon L.} and Emilio Perucca and Torbjorn Tomson and Samuel Wiebe and Zhang, {Yue Hua} and Zuberi, {Sameer M.}",
note = "Funding Information: Ingrid Scheffer received support from and/or has served as a paid consultant for UCB, Eisai, Athena Diagnostics, GlaxoSmithKline, Transgenomics, and Biocodex. She is on the editorial board of and . She has received grants from the NHRMC, ARC, NIH, HRC, CURE, US Department of Defense, and March of Dimes. The Epilepsy Study Consortium pays Jacqueline French's university employer for her consultant time related to Acorda, Anavex, Brabant Pharma, Bio‐Pharm Solutions, Eisai Medical Research, GlaxoSmithKline, GW Pharma, Impax, Johnson and Johnson, Marinus, Neusentis, Novartis, Pfizer, Roivant, Sage, SK Life Science, Sunovion, Supernus Pharmaceuticals, Takeda, UCB, Ultragenyx, Upsher‐Smith, Vertex, Zogenix, and Zynerba; she is on the scientific advisory board for Anavex and UCB; she has received grants and research from Acorda, Alexza, Eisai Medical Research, LCGH, Lundbeck, Pfizer, SK Life Science, UCB, Upsher‐Smith, and Vertex and grants from NINDS, Epilepsy Therapy Project, Epilepsy Research Foundation, Epilepsy Study Consortium; she is on the editorial board of ,, and ; and she is an associate editor of , for which she receives a fee. Edouard Hirsch has received support from UCB and/or has served as a paid consultant for UCB, ESAI, and BIAL. Gary Mathern is partially supported by the Davies/Crandall Chair for Epilepsy Research at UCLA and is coeditor in chief for and . Solomon L. Mosh{\'e} is the Charles Frost Chair in Neurosurgery and Neurology and is funded by grants from NIH NS43209, CURE, US Department of Defense, UCB, the Heffer Family and Segal Family Foundations, and the Abbe Goldstein/Joshua Lurie and Laurie Marsh/ Dan Levitz families. He serves as Associate Editor of and is on the editorial board of ,, and . He receives from Elsevier an annual compensation for his work as Associate Editor of and royalties from two books he coedited. He received a consultant's fee from Lundbeck and UCB. Emilio Perucca has received speaker's or consultancy fees and/or research grants from the following pharmaceutical companies: Eisai, Biopharm Solutions, GW Pharma, Sanofi, SK Life Science, Sun Pharma, Takeda, and UCB Pharma. Torbj{\"o}rn Tomson has received research grants and/or speaker honoraria to his institution from the following pharmaceutical companies: Eisai, GlaxoSmithKline, Novartis, Bial, and UCB. He has also received research grants from CURE, Stockholm County Council, and EU (DG Sante). Sameer Zuberi has received research support and or speaker honoraria/consultancy fees from Epilepsy Research United Kingdom, Dravet Syndrome United Kingdom, UCB Pharma, Yorkhill Children's Charity, GW Pharma, Brabant Pharma, and Zogenix. He is Editor in Chief of the . The remaining authors have no conflicts of interest. We confirm that we have read the Journal's position on issues involved in ethical publication and affirm that this report is consistent with those guidelines. Neurology Epileptic Disorders Lancet Neurology Neurology Today Epileptic Disorders Epilepsia Epilepsia Epilepsia Open Neurobiology of Disease Brain and Development Pediatric Neurology Physiological Research Neurobiology of Disease European Journal of Paediatric Neurology Publisher Copyright: {\textcopyright} 2016 The Authors. Epilepsia Open published by Wiley Periodicals Inc. on behalf of International League Against Epilepsy.",
year = "2016",
month = sep,
day = "1",
doi = "10.1002/epi4.5",
language = "English (US)",
volume = "1",
pages = "37--44",
journal = "Epilepsia Open",
issn = "2470-9239",
publisher = "Wiley-Blackwell Publishing Ltd",
number = "1-2",
}